XLO Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -4.12%, SMA50 -12.85%, SMA200 -24.92%). The stock’s 14-day RSI is 37.2 (weak momentum), while the ATR of 0.04 points to tighter daily ranges. The stock remains sitting in the mid-range of its 52-week band, trading -54.52% below its high and over 6.7% above its low. Average 10-day trading volume of 66.80 thousand shares is slightly above the 3-month average of 50.68 thousand, indicating heightened recent market interest.

Xilio Therapeutics, Inc. generated EPS of -$0.66 over the past year. Five-year average earnings growth is -11.55%. The latest quarter delivered EPS of -$0.58. The next quarter is forecast at $nan. Next year's EPS is expected at $5.50. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $2.00 to $2.00. The high target offers -77.01% upside. The low target suggests -77.01% downside. The mean target is $2.00. This offers -77.01% upside. Xilio Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -12.12%. The prior quarter beat by -49.4%. Over the last six quarters, Apple has recorded several small beats. These include -9.09% in March 11, 2025.

Xilio Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $17.48. This means the shares are trading below this model’s fair value.

Xilio Therapeutics, Inc. has 51.83 million shares outstanding. The public float is 23.43 million shares, elevated short interest at 12.14% of float. This equals 4.30 million shares. The short ratio is 9.4 days. Institutional investors hold 72.58% of the float. Insiders own 28.58%. GILEAD SCIENCES, INC. holds 40.38 million shares, Bain Capital Life Sciences Investors, LLC has 2.80 million shares and SV7 Impact Medicine Fund LP has 1.61 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Xilio Therapeutics, Inc. (NASDAQ:XLO) closed at $8.61 USD, gaining $0.05 (0.58%) from the previous close of $8.56. The stock is currently mid-range between its 52-week high and low $6.47 and $12.74. With a market capitalization of about $56.61 million, Xilio Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.12). Key stats such as the average daily volume over the past year has been around 50.48 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Xilio Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Rene Russo, the company employs approximately 76 people and listed since October 22, 2021. Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients.

Our AI price prediction model suggests that Xilio Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.1%, with price expected at $8.43 by August 04, 2026, within a range of $8.10 to $8.73 3-Month Outlook: Projected rise of 38.62%, reaching $12.06 by October 19, 2026, with a range of $11.57 to $12.55. 1-Year Outlook: Projected gain of 19.66%, with price at $10.41 by July 21, 2027, within a range of $0.00 to $12.39.

Xilio Therapeutics, Inc. (NASDAQ:XLO) shares are flat -2.22% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Xilio Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.6. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $14.12, suggesting 62.3% upside. Our AI forecast model points to short-term weakness (-3.1% over two weeks), a medium-term rise (38.62% over three months), and a longer-term gain (19.66% over one year), with expected trading ranges indicating moderate volatility.

Xilio Therapeutics, Inc. trades at a P/E ratio of -1.6, slightly below the S&P 500 average, with a price-to-sales ratio of 1.08 and a price-to-book ratio of 19.83 reflecting a rich premium to book value. The P/FCF stands at -1.01, also above market averages. Compared to sector medians, Xilio Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.